Boltz, an AI drug design company spun out of MIT, has raised $110 million in a Series A round led by Bessemer Venture Partners. The company announced the deal on November 18, 2026.

The round comes about ten months after Boltz raised a $28 million seed round in January. Boltz did not disclose a valuation.

Boltz Series A funding: deal terms and investors

Bessemer led the round, with partners Andrew Hedin and Byron Deeter working on the deal. Returning backers include Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures.

New investors in the Boltz funding round include Greycroft, F-Prime Capital, Hummingbird and lab software company Benchling.

DetailBoltz Series A
Amount$110 million
Lead investorBessemer Venture Partners
AnnouncedNovember 18, 2026
ValuationNot disclosed
Previous round$28 million seed (January 2026)
Total disclosed funding$138 million
Boltz funding rounds ($ millions) Boltz funding rounds ($ millions) Boltz funding rounds ($ millions) $0M $50M $100M $150M $28M Seed (Jan 2026) $110M Series A (Nov 2026) Boltz funding rounds ($ millions) Boltz funding rounds ($ millions) Boltz funding rounds ($ millions) $0M $50M $100M $150M $28M Seed (Jan 2026) $110M Series A (Nov 2026)
Boltz funding rounds ($ millions)

The Series A is nearly four times the size of the seed round. Amplify, a16z and Zetta led that earlier round, and Hugging Face CEO Clem Delangue was among its backers.

What Boltz builds for drug discovery

Gabriele Corso, Jeremy Wohlwend and Saro Passaro founded Boltz. All three worked in Regina Barzilay’s research group at MIT before turning the project into a public benefit corporation on January 8, 2026.

Corso is the CEO.

Open-source Boltz models

The team released Boltz-1 in November 2024. The model predicts how proteins and other molecules fold and fit together, and the team said it matched the accuracy of Google DeepMind’s AlphaFold 3.

Boltz-2 added a prediction of the binding strength between a molecule and its target. A third open model, BoltzGen, handles protein design.

According to Bessemer, the open models have passed 5 million downloads and reach more than 100,000 scientists.

Proprietary models and Boltz Lab

On June 16, 2026, Boltz launched two paid models. BoltzMol-1 finds small-molecule drug candidates and confirmed hits on six of 10 difficult targets after testing 28 to 51 compounds per target.

BoltzProt-1 designs proteins. It nearly tripled the BoltzGen hit rate on nanobody design.

Scientists run these models through Boltz Lab, a platform launched with the seed round. Customers pay in “molecular tokens,” buying usage as each experiment needs it.

An API also lets AI coding agents such as Claude Code, Codex and Gemini call the models.

Boltz usage growth and pharma partners

Molecular token usage on Boltz grew 50-fold between June and November. Usage reached about eight times the June level by August, passed 25 times in late October and hit 50 times on November 8.

Boltz molecular token usage (multiple of June level) Boltz molecular token usage (multiple of June level) Boltz molecular token usage (multiple of June level) 0x 20x 40x 60x 1x 8x 25x 50x June 2026 August 2026 Late October 2026 November 8, 2026 Boltz molecular token usage (multiple of June level) Boltz molecular token usage (multiple of June level) Boltz molecular token usage (multiple of June level) 0x 20x 40x 60x 1x 8x 25x 50x June 2026 August 2026 Late October 2026 November 8, 2026
Boltz molecular token usage (multiple of June level)

Six of the world’s 20 largest drug companies now work with Boltz, including Pfizer, GSK, Takeda and Bristol Myers Squibb. The Pfizer deal is a multi-year collaboration announced alongside the January launch.

How Boltz plans to use the $110 million

Boltz will spend the new capital on computing capacity, data and hiring, according to The Pharma Letter. The company employs about 40 scientists and engineers.

Corso has said the next generation of Boltz models already produces better molecules than the current releases.

Boltz funding and the AI drug discovery market

The Boltz round landed one day after Isomorphic Labs announced a $5 billion Series C. Isomorphic’s earlier $2.1 billion round ranked among the biggest AI funding rounds of Q2 2026.

Chai Discovery, which also builds AI models for molecular design, raised a $400 million Series C in July at a $3.8 billion valuation. Both companies appear on AI Funding Tracker’s list of top AI healthcare startups by valuation and funding.

CompanyRoundAmountAnnounced
Isomorphic LabsSeries C$5 billionNovember 17, 2026
Chai DiscoverySeries C$400 millionJuly 14, 2026
BoltzSeries A$110 millionNovember 18, 2026

Boltz is at an earlier stage than both companies. It sells access to its models by usage, while Isomorphic is moving its own drug candidates toward clinical trials.

FAQ

How much did Boltz raise in its Series A?

Boltz raised $110 million in a Series A round announced on November 18, 2026. Bessemer Venture Partners led the round.

Total disclosed funding now stands at $138 million.

Who invested in the Boltz funding round?

Bessemer led the round. Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures returned, while Greycroft, F-Prime Capital, Hummingbird and Benchling joined as new investors.

What does Boltz do?

Boltz builds AI models that predict molecular structures and design proteins and small-molecule drugs. It offers open-source models plus paid models through its Boltz Lab platform.

What is the Boltz valuation?

Boltz has not disclosed a valuation for its Series A round.

Which pharma companies work with Boltz?

Six of the world’s 20 largest drug companies are partners, including Pfizer, GSK, Takeda and Bristol Myers Squibb. Pfizer signed a multi-year collaboration in January 2026.

Sheldon researches company ownership and business models for AIFundingtracker.com, covering who controls tech and AI companies and how they make money. He also writes plain-language guides to online platforms and what readers should know before using them.

Leave A Reply